Xeris Biopharma Holdings Inc (NASDAQ: XERS) is 45.11% higher on its value in year-to-date trading and has touched a low of $1.69 and a high of $3.87 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The XERS stock was last observed hovering at around $3.25 in the last trading session, with the day’s gains setting it 0.16%.
Currently trading at $3.41, the stock is 0.72% and 5.61% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.54 million and changing 4.92% at the moment leaves the stock 34.25% off its SMA200. XERS registered 66.34% gain for a year compared to 6-month gain of 61.61%. The firm has a 50-day simple moving average (SMA 50) of $3.2168 and a 200-day simple moving average (SMA200) of $2.5354.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 13.29% loss in the last 1 month and extending the period to 3 months gives it a 16.38%, and is 0.29% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.76% over the week and 5.06% over the month.
Xeris Biopharma Holdings Inc (XERS) has around 377 employees, a market worth around $508.36M and $187.36M in sales. Profit margin for the company is -33.69%. Distance from 52-week low is 101.78% and -11.89% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.49%).
with sales reaching $56.74M over the same period.The EPS is expected to grow by 20.54% this year, but quarterly earnings will post 21.83% year-over-year. Quarterly sales are estimated to grow 27.82% in year-over-year returns.
186.0 institutions hold shares in Xeris Biopharma Holdings Inc (XERS), with institutional investors hold 45.62% of the company’s shares. The shares outstanding are 149.00M, and float is at 141.35M with Short Float at 7.01%. Institutions hold 43.84% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 10.33 million shares valued at $23.25 million. The investor’s holdings represent 7.3531 of the XERS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 7.66 million shares valued at $17.23 million to account for 5.4492 of the shares outstanding. The other top investors are CAXTON CORP which holds 5.11 million shares representing 3.639 and valued at over $11.51 million, while BIOIMPACT CAPITAL LLC holds 3.4378 of the shares totaling 4.83 million with a market value of $10.87 million.
Xeris Biopharma Holdings Inc (XERS) Insider Activity
The most recent transaction is an insider purchase by Schmid John P., the company’s Director. SEC filings show that Schmid John P. bought 4,515 shares of the company’s common stock on Aug 12 ’24 at a price of $2.25 per share for a total of $10147.0. Following the purchase, the insider now owns 25200.0 shares.
Xeris Biopharma Holdings Inc disclosed in a document filed with the SEC on Aug 09 ’24 that Schmid John P. (Director) bought a total of 4,285 shares of the company’s common stock. The trade occurred on Aug 09 ’24 and was made at $2.37 per share for $10134.0. Following the transaction, the insider now directly holds 20685.0 shares of the XERS stock.
Still, SEC filings show that on May 10 ’24, Schmid John P. (Director) acquired 5,400 shares at an average price of $1.91 for $10314.0. The insider now directly holds 16,400 shares of Xeris Biopharma Holdings Inc (XERS).
